Presently, Peter S. García is Chief Financial Officer at ALX Oncology Holdings, Inc.

He is also on the board of DURECT Corp., Moraga Biotechnology Corp. and Noden Pharma USA, Inc.

He previously was CFO, Head-Investor & Media Relations at Lineage Cell Therapeutics, Inc. and Chief Financial Officer of Asterias Biotherapeutics, Inc. (a subsidiary of Lineage Cell Therapeutics, Inc.), Chief Financial Officer at Nanosys, Inc., Chief Financial Officer & Vice President at PDL BioPharma, Inc., Chief Financial Officer, Secretary & IR Contact at Adhera Therapeutics, Inc. and Chief Financial Officer & Secretary for MDRNA, Inc. (a subsidiary of Adhera Therapeutics, Inc.), Chief Financial Officer of Novacept, Inc., Principal at Amgen, Inc., Principal at Teradata Corp., Chief Financial Officer & Senior Vice President for Nuvelo, Inc., Chief Financial Officer at IntraBiotics Pharmaceuticals, Inc., Chief Financial Officer for Dendreon Corp. and Chief Financial Officer of CYTYC Surgical Products.

Peter S. García received an MBA from the University of California, Los Angeles and an undergraduate degree from Stanford University.